ArticleFrontiers in cellular and infection microbiology2026
No improvement in clinical outcomes: a propensity score analysis of inappropriate carbapenem use in children with susceptible
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Secondary hypoalbuminemia is independently associated with in-hospital mortality in children withAnnals of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine whether carbapenem overuse affects clinical outcomes in children with susceptible Methods: We conducted a retrospective study of 206 pediatric patients with Results: After PSM, all covariates were balanced (standardized mean differences <0.2). Overall mortality was 10.68%. No significant differences were observed between the inappropriate carbapenem group and the standard therapy group regarding mortality, sepsis, septic shock, or duration of hospitalization, in both unmatched and matched analyses. In the matched cohort, no significant associations were observed for mortality (OR 0.75, 95% CI 0.26-2.16, p= 0.594), sepsis (OR 0.93, 95% CI 0.44-1.98, p=0.847), septic shock (OR 0.83, 95% CI 0.25-2.73, p=0.776). Likewise, no significant between-group difference in duration of hospitalization was detected via the paired Wilcoxon signed-rank test (p = 0.777). Conclusions: No significant differences in mortality, sepsis, septic shock, or duration of hospitalization were observed between the inappropriate carbapenem group and the standard therapy group. These findings reinforce the importance of antimicrobial stewardship by demonstrating that initial narrow-spectrum therapy (third-generation cephalosporins) achieves comparable outcomes, thereby reducing unnecessary carbapenem exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.